2 514

Cited 13 times in

Comparative effectiveness of bevacizumab plus cisplatin-based chemotherapy versus pemetrexed plus cisplatin treatment in East Asian non-squamous non-small cell lung cancer patients applying real-life outcomes

Authors
 Gee-Chen CHANG  ;  Myung-Ju AHN  ;  Elaine WRIGHT  ;  Heung Tae KIM  ;  Joo-Hang KIM  ;  Jin Hyoung KANG  ;  Sang-We KIM  ;  Steven SHERMAN  ;  Stefan WALZER 
Citation
 ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol.7(Suppl.2) : 34-40, 2011 
Journal Title
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
ISSN
 1743-7555 
Issue Date
2011
MeSH
Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal, Humanized ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use* ; Bevacizumab ; Carcinoma, Non-Small-Cell Lung/drug therapy* ; Cisplatin/administration & dosage ; Disease-Free Survival ; Far East ; Female ; Glutamates/administration & dosage ; Guanine/administration & dosage ; Guanine/analogs & derivatives ; Humans ; Lung Neoplasms/drug therapy* ; Male ; Middle Aged ; Pemetrexed ; Survival Analysis ; Treatment Outcome ; Young Adult
Keywords
antineoplastic combined chemotherapy protocol ; Asia ; bevacizumab ; comparative study ; non‐small cell lung carcinoma
Abstract
AIM: To indirectly compare real-life clinical effectiveness of bevacizumab + cisplatin-based therapy from the Safety of Avastin in Lung (SAiL) phase IV clinical trial with published evidence from the phase III clinical trial for pemetrexed + cisplatin among East Asian patients with non-squamous metastatic or recurrent non-small cell lung cancer (NSCLC).

METHODS: Survival outcomes were compared between subgroups of East Asian patients receiving treatments of either bevacizumab + cisplatin-based chemotherapy or pemetrexed + cisplatin using a matching-adjusted indirect comparison approach. Patient-level data were used to derive a new group with similar characteristics compared to those reported in a phase III clinical trial evaluating pemetrexed + cisplatin therapy. Exclusions to the SAiL data included those with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 2, those with mixed cell histology, non-East Asians and those who did not receive cisplatin-based chemotherapy. In total 1000 samples of the pre-matched analysis set of the SAiL data were selected that resulted in equal distributions of the ECOG PS and gender matching variables selected and evaluated for a progression-free survival (PFS) outcome.

RESULTS: Median PFS was longer for patients treated with bevacizumab-based therapy (7.4 months; 95% confidence interval [CI]: 6.7-8.2) versus pemetrexed + cisplatin (6.4 months; 95% CI N/A) among non-squamous East Asian NSCLC patients.

CONCLUSION: The results suggest that East Asian non-squamous NSCLC patients treated with bevacizumab-based therapy have a trend toward improved PFS outcomes compared to those treated with pemetrexed + cisplatin, even after adjusting for differences between the two trial groups.
Full Text
http://onlinelibrary.wiley.com/doi/10.1111/j.1743-7563.2011.01400.x/abstract
DOI
10.1111/j.1743-7563.2011.01400.x
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Joo Hang(김주항)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/94872
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links